CMS Bureau Francis Lefebvre has taken part in the process and the implementation of social aspects for the merger and acquisition between Astrazeneca and Minakem

Astrazeneca Dunkerque Production, a subsidiary company of the Astrazeneca Group, located at Dunkerque, has transfered its production activity of active principles to the Minakem fine chemistry group but keeps up its medicine production unit located on the same site. The 146 salaried employees of the chemical site of Astrazeneca in Dunkerque have changed one’s employer following this transfer.

Astrazeneca also has transfered its property assets where the chemistry activity was exploited. Contracts have been entered into concomitantly to the transfer between Astrazeneca Dunkerque and Minakem in order to ensure the durability of the supply of AstraZeneca and the business of this major industry site. A few of service provisions between the two groups, which will become gradually independent from each other, have been arranged.

A team of the Lefèvre-Pelletier law firm headed by Jacques Epstein (Muriel Perrier for the law of contract, Marie-Anne Fabre for corporate, Pascaline Dechelette and Valérie Moskal in property law, Marie-Daphné Fischelson and Mathilde Plenat for employment law) has advised the Astrazeneca group for the conclusion of this transaction.

Jacques Nicolas, partner and Vincent Delage, CMS Bureau Francis Lefebvre lawyers, were advisers for the social aspects of these transfers.

Niels Dejean from Shearman & Sterling advised Astrazeneca in tax law.

Barbier Carpentier Thibault Groener & Associés (Marc Barbé and Séverin Kullmann, partners and Ambroise Jeannot) counselled Minakem.

For further information, please contact :
CMS Bureau Francis Lefebvre
Florence Jouffroy / Tel: +33 1 47 38 40 32
Laetitia Mostowski / Tel: +33 1 47 38 40 74